First-line treatment of chronic myeloid leukemia: Imatinib versus nilotinib and dasatinib

Community Oncology

Volumn 8, Issue 2, 2011, Pages 65-72

  DiBella, Nicholas J ^a  

^a ROCKY MOUNTAIN CANCER CENTERS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; DASATINIB; IMATINIB; NILOTINIB;

ALOPECIA; ANEMIA; BLEEDING; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DIARRHEA; DRUG APPROVAL; DRUG CHOICE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG RESISTANCE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; EYELID EDEMA; FATIGUE; FLUID RETENTION; FOOD; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART INFARCTION; HEART RIGHT VENTRICLE EJECTION FRACTION; HUMAN; HYPOPHOSPHATEMIA; LOW DRUG DOSE; MUSCLE SPASM; MUSCULOSKELETAL PAIN; MYALGIA; MYOSITIS; NAUSEA; NEUTROPENIA; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PLEURA EFFUSION; PRURITUS; QT INTERVAL; QT PROLONGATION; REVIEW; SIDE EFFECT; SUDDEN DEATH; THROMBOCYTOPENIA; VOMITING;

EID: 79952169683     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(12)70039-6     Document Type: Review

References (25)

1. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-2270.
2. Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-2259.
3. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
4. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.
5. Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib [abstract]. Blood 2009;114:1126.
6. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358-3363.
7. Cortes J, Kantarjian H, Goldberg S, et al. High-dose imatinib in newly diagnosed chronic- phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol 2009;27:4754-4759.
8. Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010;28:424-430.
9. Hehlmann R, Jung-Munkwitz S, Lauseker M, et al. Randomized comparison of imatinib 800 mg vs imatinib 400 mg +/- IFN in newly diagnosed BCR/ABL positive chronic phase CML: analysis of molecular remission at 12 months [abstract]. Blood 2009;114:339.
10. Mahon F-X, Réa D, Guilhot F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-1035.
11. Weisberg E, Manley PW, Breitenstein W. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-141.
12. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5- carboxamide (BMS-354825), a dual Src/ Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-6661.
13. Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006;108:1478-1484.
14. Quintás-Cardama A, Kantarjian H, Jones D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 2009;113:6315-6321.
15. Cervantes F, Baccarani M, Lipton J, et al. Dasatinib long-term efficacy in patients with chronic myeloid leukemia in chronic phase (CML-CP) with resistance or intolerance to imatinib: a two-year update of the START-C study [abstract]. Haematologica 2008;93:372.
16. Kantarjian H, Pasquinin R, Levy V, et al. Dasatinib or high-dose imatinib for chronic- phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009;115:4136-4147.
17. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance or intolerance. Blood 2007;110:3540-3546.
18. Kantarjian H, Giles F, Bhalla K, et al. Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes [abstract]. Blood 2009;114:1129.
19. Jabbour E, Jones D, Kantarjian HM, et al. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 2009;114:2037-2043.
20. Jabbour E, Kantarjian H, Cortes J. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one? Semin Hematol 2010;47:344-353.
21. Müller MC, Cortes JE, Kim D-W, et al. Dasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to pre-existing BCR-ABL mutations. Blood 2009;114:6914-6915.
22. Jabbour E, Kantarjian H, O'Brien S, et al. Predictive factors for response and outcome in patients (pts) treated with secondgeneration tyrosine kinase inhibitors (2-TKI) for chronic myeloid leukemia in chronic phase (CML-CP) post imatinib failure [abstract]. Blood 2009;114:210.
23. Tasigna [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2010.
24. Sprycel [package insert]. Princeton, NJ: Bristol-Myers Squibb Co.; 2010.
25. Gleevec [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2003.